-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster II

Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 2, 2018: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Na Shen1*, Xiaojian Zhu2*, Shu Zhou1*, Yong You1*, Zhaodong Zhong, PhD1*, Xiaoying Zhu1*, Qing Li, PhD3*, Ping Zou1* and Yicheng Zhang4

1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3Department of Hematology, Wuhan No.1 Hospital, Wuhan, China
4Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Kibeom Jang, PhD1* and Neil P. Shah, MD, PhD2,3

1UCSF, San Francisco, CA
2Department of Medicine/Hematology-Oncology, UCSF School of Medicine, San Francisco, CA
3Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA

Margaret Nieborowska-Skorska1*, Paulina Podszywalow-Bartnicka2*, Silvia Maifrede1*, Bac Viet Le1*, Monika Toma3*, Peter Valent4, Tomasz Sliwinski3*, Wayne Childers5*, Katarzyna Piwocka2*, Alexei Tulin6* and Tomasz Skorski, MD, PhD1

1Temple University School of Medicine, Philadelphia, PA
2Nencki Institute of Experimental Biology, Warsaw, Poland
3University of Lodz, Lodz, Poland
4Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
5Temple University School of Pharmacy, Phialdelphia, PA
6University of North Dacota, Grand Forks, ND

Daniel Thomson, PhD, BSc1,2*, Hezrin Shahrin, PhD2,3*, Paul Wang, PhD3,4*, Carol Wadham, PhD2,3*, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA5, Andreas Schreiber, PhD3,4* and Susan Branford, PhD2,3

1Centre for Cancer Biology, Adelaide, SA, Australia
2Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia
3Centre for Cancer Biology, Adelaide, Australia
4ACRF Cancer Genomic Facility, Adelaide, Australia
5Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

Constance Baer, PhD1, Wolfgang Kern, MD1, Torsten Haferlach, MD2 and Claudia Haferlach, MD1

1MLL Munich Leukemia Laboratory, Munich, Germany
2MLL Munchner Leukamie Labor Gmbh, Munchen, Germany

Kyle Spinler, BS, DPhil1, Tannishtha Reya, PhD2, Jeevisha Bajaj, PhD3, Takahiro Ito4*, Bryan Zimdahl, PhD5*, Armin Ahmadi, BS6*, Claire Koechlein7*, Nikki Lytle8*, Hyog Young Kwon, PhD6*, Ferdous Anower-E-Khuda, PhD6*, Marcie Kritzik6*, Jan Karlseder9*, Pyong Woo Park, PhD10* and Jeffrey Esko, PhD6*

1Pharmacology, University of California San Diego, San Diego, CA
2University of California, San Diego, La Jolla, CA
3Pharmacology, University of California, San Diego, La Jolla, CA
4University of Georgia, Athens, GA
5University of California San Diego, Emeryville, CA
6University of California San Diego, La Jolla
7University of California San Diego, La Jolla, CA
8University of California San DIego, La Jolla
9The Salk Institute For Biological Studies, San Diego, CA
10Boston Children's Hospital, Boston

Mieszko Lachota*, Marta Siernicka, MSc*, Zofia Pilch, PhD*, Agnieszka Graczyk-Jarzynka, PhD* and Magdalena Winiarska, PhD*

Department of Immunology, Medical University of Warsaw, Warsaw, Poland

*signifies non-member of ASH